3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
5
Lung Neoplasms
2
Rhabdoid Tumor
1
Papillary renal cell carcinoma, sporadic
1
Oropharyngeal Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Mouth Neoplasms
1
Melanoma
1
Laryngeal Neoplasms
1
Kidney Neoplasms
1
Hypopharyngeal Neoplasms
1
Hereditary leiomyomatosis and renal cell cancer
1
Head and Neck Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Choroid Plexus Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma
1
Breast Neoplasms
1
Interventions
Carboplatin
15
Etoposide
13
atezolizumab
9
Topotecan
8
durvalumab
7
Specimen Handling
7
PM 01183
6
Cisplatin
5
pembrolizumab
4
Magnetic Resonance Spectroscopy
4
Irinotecan
4
Injections
3
Biopsy
3
berzosertib
2
Nivolumab
2
Fulvestrant
2
Drug Therapy
2
AMG 757
2
tremelimumab
1
trastuzumab deruxtecan
1
toripalimab
1
tazemetostat
1
palbociclib
1
olaparib
1
lenvatinib
1
fludarabine
1
enzalutamide
1
cabozantinib
1
budigalimab
1
arginine decarboxylase
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Small Cell Lung Carcinoma
×
Erlotinib Hydrochloride
×
30 days
×
Clear all
No trials found.